WW says Sequence being impacted by GLP-1 supply constraints

Asked during the Morgan Stanley Global Healthcare Conference about how supply constraints across GLP-1s have impacted Sequence, executives from WW said: “So I’ll talk about the supply constraints. And obviously, they are impacting us in the space in general. There are supply constraints going on in the space. And, what I would share is all the good work we’re doing to ready for when supply returns or starts to grow back to a normal or consistent growth rate. So, during this time, we are leaned into working on our integration, so integrating Weight Watchers and Sequence into a common platform, integrating the experience into our app. Getting ready our GLP-1 Companion Program to launch ahead of peak season. And by that, I mean, members can come into Weight Watchers and sign up for our core program, and it is a healthy habit building behavior change a based program. You can identify on the way into that program as I’m diabetic. And we’re going to give you a tailored diabetic program, et cetera. We work to tailor to your needs. And we will be tailoring and launching program tailored to the needs of people on a GLP-1 program and launching that ahead of our peak season, and that will be complementary to a sequent subscriber, but also available to our general membership because there will be people who come through that would like the GLP-1 behavior change support, but maybe they have access elsewhere or maybe they don’t have an insurance need or some of the needs that are built into what we’re providing the team has spoke to, within Sequence. So we’re leaned into integration. We’re also leaned into testing and learning during this time frame. We’ve not really unleashed marketing yet. Sima can speak to the marketing efforts, but we’re readying and testing and thinking about what to do from a marketing perspective when the time comes that we’re comfortable that supply is returning.”